Announced Sat, 25 Apr · 11:58 IST
USFDA Final Approval for Alembic's Fingolimod Capsules 0.5 mg
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.9%1-day move
₹753.00
prior close
₹784.85
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-1.8-1.9-1.5+0.9+1.1+0.0+1.8+2.3+2.6-0.0-0.1+4.4+8.3
Up moveDown movePending
AI summary
Alembic Pharmaceuticals received USFDA final approval for its generic Fingolimod Capsules 0.5 mg, therapeutically equivalent to Novartis's Gilenya, used for relapsing forms of multiple sclerosis. The drug addresses an estimated US$145 million market (12 months ending Dec 2025, per IQVIA). Alembic now holds 237 cumulative ANDA approvals from USFDA (219 final, 18 tentative), reinforcing its US generics pipeline.
Likely market impact
Positive for Alembic's US generics business; entry into a $145M addressable market supports future revenue, though generic pricing pressure is expected.